Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 9/20 | 0.63 |
| ▸ | USP2 | O75604 | 8/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.63 |
| ▸ | LMNA | P02545 | 7/20 | 0.63 |
| ▸ | CLK4 | Q9HAZ1 | 7/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.63 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 6/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2156146 | 0.86 | MEN1 (0.60) | CYP1A2CYP3A4CYP2C19USP2CYP2D6 | |
| SCHEMBL2154983 | 0.86 | ABCG2 (0.65) | CYP1A2CYP3A4CYP2C19USP2CYP2D6 | |
| SCHEMBL14727858 | 0.85 | CLK4 (0.58) | CYP1A2CYP3A4CYP2C19USP2CYP2D6 | |
| SCHEMBL2155882 | 0.84 | CYP1A2 (0.65) | CYP1A2CYP3A4CYP2C19USP2CYP2D6 | |
| SCHEMBL14474124 | 0.84 | CYP1A2 (0.62) | CYP1A2CYP3A4CYP2C19USP2CYP2D6 | |
| SCHEMBL2154624 | 0.81 | CYP1A2 (0.60) | CYP1A2CYP3A4CYP2C19USP2CYP2D6 | |
| SCHEMBL14474065 | 0.80 | LMNA (0.63) | CYP1A2CYP3A4CYP2C19USP2CYP2D6 | |
| SCHEMBL17212414 | 0.80 | SYK (0.66) | CYP1A2CYP3A4CYP2C19USP2CYP2D6 | |
| SCHEMBL14727573 | 0.79 | CYP1A2 (0.61) | CYP1A2CYP3A4CYP2C19USP2CYP2D6 | |
| SCHEMBL16183451 | 0.79 | CYP1A2 (0.58) | CYP1A2CYP3A4CYP2C19USP2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-3056207-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| WO-2013003586-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | CYP1A2 4552/4885CYP3A4 4815/4885CYP2C19 4818/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | CYP1A2 4619/4885CYP3A4 4805/4885CYP2C19 4822/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | CYP1A2 4552/4885CYP3A4 4815/4885CYP2C19 4818/4885 |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | CYP1A2 2971/4885CYP3A4 4456/4885CYP2C19 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.